MarketResearchNest.com adds latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis – Pipeline Review, H2 2017, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape. The report spread across in 90 pages with tables and figures in it.
Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.
Pharmaceutical and Healthcare latest pipeline guide Liver Cirrhosis – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Liver Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Inquire for Discount at https://www.marketresearchnest.com/requestdiscount.php?reportid=253112 .
Liver Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Liver Cirrhosis – Companies Involved in Therapeutics Development: Conatus Pharmaceuticals Inc,,nGalectin Therapeutics Inc, Gilead Sciences Inc, Human Stem Cells Institute, Immunitor Inc, International Stem Cell Corp, Ocera Therapeutics Inc, Pharmicell Co Ltd & VESSL Therapeutics Ltd.
Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=253112
Liver Cirrhosis – Drug Profiles:
BCD-800, Cell Therapy for Liver Cirrhosis, Cellgram-LC, emricasan, Gemacell, GMCT-01, GRMD-02, GXHPC-1, ND-654, ornithine phenylacetate, Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis, Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis, Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis, Pneumoconiosis and Rheumatoid Arthritis, Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis, Stem Cell Therapy to Activate ZSCAN4 for Liver Cirrhosis, V-5.
Featured News & Press Releases
Jun 16, 2017: Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference
Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting
Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis
May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial
Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting
Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial
Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting
Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting
Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting
Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement
May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam
Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting
Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Liver Cirrhosis (Gastrointestinal).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Liver Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Request a Sample Copy at https://www.marketresearchnest.com/requestsample.php?reportid=253112 .
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain